Twitter Beğeni Hilesi

Different paths to #precisionOncology. For trainees (and indeed all of us), if you see a talk or subject that moves you, don't be afraid to seek out the speaker. You never know where it might lead. Related, see nature.com/articles/s4159… by Eli Van Allen

As my very first post on twitter, I am very excited to announce that our article "Identification of cancer driver genes based on nucleotide context" appeared in Nature Genetics today. Here is the link to our study: rdcu.be/b08OU

Beautiful comut data visualization, open-source package from Jett Crowdis, @vanallenlab! See biorxiv.org/content/10.110…

A #COVID19 battle story. This week #COVID19 became very real. This virus that has been passed all over the globe and has afflicted more than 1 million people has now infected me. Here, in my corner of the world in Durham, NC. I am 1 of ~300 +cases Duke Health and ~2100 in NC. 1/n

Auctions are great ways to allocate scarce resources to areas of need. But 50 states+fed govt competing for PPE and critical equipment is ridiculous. Why not a single fed govt purchase, then an internal auction/bidding system with points allocated by state population/need?

Predicting who is likely or unlikely to respond to checkpoint inhibitors remains a focus for researchers. ms.spr.ly/6010T5Tiw

Looking for COVID19 papers and data curated by well-trained, thoughtful scientists and experts? Follow @JHU_NCRC or at the coming website linked to the Johns Hopkins COVID tracking dashboard.

Wow, highest documented seropositive rate I have seen in world! 200 random sample Chelsea, MA 32% test positive antibody J. Iafrate MassGeneral News pathology Nearly a third of 200 blood samples taken in Chelsea show exposure to coronavirus bostonglobe.com/2020/04/17/bus…

FDA pembro label details only 41 patients have PK data treated with 400mg q6. In the nivo FDA label, the PK data are not even mentioned. I'm not saying we shouldn't use the extended dosing... Efficacy will be equal. But we must be alert to new AE signals, esp infusional.

Have you heard? Our website (ncrc.jhsph.edu) is up and running. We prioritize original research for public health action and papers receiving significant press, regardless of quality. Experts work in eight teams to summarize select papers about #SARSCoV2 and #COVID19

Join us in congratulating our five Physician-Scientist Training Awardees. Full story: bit.ly/2LxVHtS @meyersonlab Dana-Farber Harvard Medical School Jonathan Dudley, M.D. Ludwig Cancer Johns Hopkins Medicine Rockefeller University @sloan_kettering Stanford Medicine Natalie Vokes Eli Van Allen

#AACR20 Plenary: Dr. Ashi_W presents work of Dr. Gretchen Alicea Ph.D. @JHSPHBMB et al on relationship btwn aging tumor microenvironment & diminished response to therapy w/ aging in #melanoma. Full publication here: bit.ly/315li6z. #melsm #LatinxInMedicine #WomenInSTEM

Tweetorial of a very relevant COVID19 antibody study with (IMPORTANTLY) thoughtful context and interpretation. (note: not yet peer-reviewed)

The intriguing case of a man with melanoma tumors that responded in different ways to the same checkpoint-blocking drug has yielded an important clue to the causes of resistance to immunotherapy treatments, according to Dana-Farber researchers. ms.spr.ly/6014TWxqp

Dr. Costa was my attending in residency. I vividly remember being on call overnight, caring for very sick patients on the floor, & feeling so much calmer when Dr. Costa came to help. He was kind and brilliant. This weekend he died of covid in his own ICU. baltimoresun.com/coronavirus/bs…

Here's our latest in Nature Genetics - we dug into > 1k melanoma exomes to search for secondary molecular drivers & interactions in biological and clinical contexts Congrats to Methuen High School's own Jake Conway et al! A few brief points: rdcu.be/cbcd4 [1/6]

Congratulations Alex Shoushtari, MD , Niki Schultz, Allison Betof Warner, MD, PhD and co-authors on this thoughtfully conducted deep dive into melanoma subtypes!